--- title: "Reverse Stock Split Strengthens HealthLynked’s Market Position as Company Scales AI-Driven Healthcare Platform | HLYK Stock News" description: "HealthLynked Corp. has completed a reverse stock split to strengthen its market position and enhance shareholder value. This strategic move aims to improve capital structure and attract institutional " type: "news" locale: "en" url: "https://longbridge.com/en/news/255997503.md" published_at: "2025-09-04T16:07:00.000Z" --- # Reverse Stock Split Strengthens HealthLynked’s Market Position as Company Scales AI-Driven Healthcare Platform | HLYK Stock News > HealthLynked Corp. has completed a reverse stock split to strengthen its market position and enhance shareholder value. This strategic move aims to improve capital structure and attract institutional investors by increasing the per-share price without diluting ownership. The company is also scaling its AI-driven healthcare platform and expanding its intellectual property portfolio. CEO Michael Dent emphasizes the commitment to long-term growth and the potential for substantial recurring revenue through partnerships with major insurance carriers. 09/04/2025 - 12:07 PM NAPLES, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB:HLYK) -- Dear Shareholders, I'm writing to share an important update in the continued evolution of HealthLynked Corp. that reflects our commitment to long-term growth and enhanced shareholder value. We've completed a strategic reduction in the number of our outstanding shares. This move—commonly referred to as a reverse stock split—is part of a broader effort to strengthen our capital structure, improve our market positioning, and align HealthLynked with the expectations of institutional investors and national trading platforms. Why This Matters By reducing the number of shares outstanding, we've increased our per-share price without impacting your percentage ownership in the Company. This is a non-dilutive step that supports greater visibility, potential uplisting opportunities, and access to a broader range of investors—including those using trading platforms that require a minimum share price for participation. This approach has been used successfully by many emerging growth companies preparing for a larger market presence, and we believe it puts HealthLynked on a similar path. Built for Growth, Ready to Scale We've recently launched our patented AI healthcare guide, ARi, and we continue to build commercial traction through our nationwide telemedicine platform and other digital services. While early in revenue generation, these platforms are gaining momentum and positioning us for scalable deployment. We are currently in discussions with major insurance carriers to integrate our technology into care management workflows—a model that could drive substantial recurring revenue across large member populations. At the same time, we are expanding our intellectual property portfolio, building on our existing patents in healthcare and AI to support future innovation and defensible market leadership. Looking Ahead The reduction in our outstanding shares is just one step in a larger plan to enhance shareholder value, attract institutional support, and scale our operations. Our vision is bold, and our technology is built for impact. We remain focused on executing that vision while keeping the long-term interests of our shareholders front and center. Thank you for your continued trust and support. We look forward to sharing more progress with you in the months ahead. Sincerely, **Michael Dent M.D.** Chief Executive Officer HealthLynked Corp. **About HealthLynked Corp** HealthLynked Corp. enhances healthcare through personalized care management that improves outcomes and reduces costs. Its cloud-based platform connects patients with providers for virtual or in-office appointments and consolidates medical records into one secure, accessible location. With AI-driven insights and integrated telehealth services, HealthLynked empowers patients and providers to coordinate care more effectively, while delivering substantial savings on prescriptions and healthcare services. The platform supports enterprise partnerships, offering scalable solutions to healthcare networks and digital health innovators. Learn more at:www.hlykgroup.com **Download the HealthLynked App:** - Apple App Store - Google Play Store **Forward-Looking Statements** This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such statements are inherently uncertain and may differ materially from actual results. Forward-looking statements reflect management's current expectations and are subject to risks, uncertainties, and assumptions. HealthLynked disclaims any obligation to update these statements except as required by law. **Investor & Media Contact** HealthLynked Corp. 1265 Creekside Parkway, Suite 200 Naples, FL 34108 Phone: +1 (800) 928-7144 Email:IR@healthlynked.com ### Related Stocks - [HLYK.US - HealthLynked Corp.](https://longbridge.com/en/quote/HLYK.US.md) - [HLYKD.US - HEALTHLYNKED CORP](https://longbridge.com/en/quote/HLYKD.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Healthlynked 向由首席执行官控制的信托发行了 570 万美元的可转换票据 | Healthlynked Corporation 向由首席执行官 Michael Dent 博士控制的 Mary S. Dent Gifting Trust 发行了一份 570 万美元的高级担保可转换票据。该票据于 2029 年 2 月 2 | [Link](https://longbridge.com/en/news/275171792.md) | | AI 淘金热变成 AI 恐慌潮！华尔街新共识：躲开一切可能被颠覆的公司 | 投资者不再热衷于寻找 AI 赢家，而是急于抛售任何可能被 AI 颠覆的公司股票，这种” 先卖出、再提问” 的恐慌情绪正在从软件行业蔓延至金融服务、财富管理、保险经纪和法律服务等多个领域。宁愿错杀也不愿承担被 AI 颠覆风险的心态正在重塑华尔 | [Link](https://longbridge.com/en/news/275557016.md) | | “AI 交易” 的关键变量：服务业敞口越高，AI 颠覆风险越大，“AI 基建” 最有利 | 大摩量化研究显示，“服务业敞口” 是 AI 投资的关键变量，与收益呈显著负相关。由于市场担忧 AI 颠覆，服务业敞口高达 53% 的 “AI 采用者” 表现垫底。相反，“AI 基础设施” 敞口仅 14%，受颠覆风险最小且受益于资本支出，在六 | [Link](https://longbridge.com/en/news/275977957.md) | | 本轮 AI 大清洗，财富管理平台被错杀了？ | 随着 AI 税务规划工具的推出，财富管理平台股价承压，市场情绪恐慌。美银美林的研报指出，这一抛售是情绪化的错杀，AI 是增强而非替代顾问的工具。高净值客户仍需人类顾问的专业建议，AI 的价值在于提升效率。报告认为，具备高净值客户基础、积极嵌 | [Link](https://longbridge.com/en/news/275890826.md) | | Molina 医疗｜10-K：2025 财年营收 454 亿美元 | | [Link](https://longbridge.com/en/news/275512865.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.